La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Bio-Techne Gestione
Gestione criteri di controllo 2/4
Bio-Techne's Il CEO è Kim Kelderman, nominato in Feb2024, e ha un mandato di meno di un anno. la retribuzione annua totale è $ 2.61M, composta da 22.6% di stipendio e 77.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.025% delle azioni della società, per un valore di $ 2.89M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 7.6 anni.
Informazioni chiave
Kim Kelderman
Amministratore delegato
US$6.9m
Compenso totale
| Percentuale dello stipendio del CEO | 11.1% |
| Mandato del CEO | less than a year |
| Proprietà del CEO | 0.03% |
| Durata media del management | 1.1yrs |
| Durata media del Consiglio di amministrazione | 7.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26
Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching
Sep 11Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings
Aug 24When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jun 09Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Aug 16Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | US$7m | US$760k | US$168m |
| Mar 31 2024 | n/a | n/a | US$203m |
| Dec 31 2023 | n/a | n/a | US$224m |
| Sep 30 2023 | n/a | n/a | US$247m |
| Jun 30 2023 | US$3m | US$590k | US$285m |
| Mar 31 2023 | n/a | n/a | US$271m |
| Dec 31 2022 | n/a | n/a | US$262m |
| Sep 30 2022 | n/a | n/a | US$292m |
| Jun 30 2022 | US$3m | US$562k | US$272m |
| Mar 31 2022 | n/a | n/a | US$225m |
| Dec 31 2021 | n/a | n/a | US$210m |
| Sep 30 2021 | n/a | n/a | US$177m |
| Jun 30 2021 | US$4m | US$530k | US$140m |
| Mar 31 2021 | n/a | n/a | US$184m |
| Dec 31 2020 | n/a | n/a | US$175m |
| Sep 30 2020 | n/a | n/a | US$248m |
| Jun 30 2020 | US$2m | US$500k | US$229m |
| Mar 31 2020 | n/a | n/a | US$187m |
| Dec 31 2019 | n/a | n/a | US$195m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | US$2m | US$452k | US$96m |
| Mar 31 2019 | n/a | n/a | US$121m |
| Dec 31 2018 | n/a | n/a | US$96m |
| Sep 30 2018 | n/a | n/a | US$128m |
| Jun 30 2018 | US$2m | US$73k | US$126m |
Compensazione vs Mercato: La retribuzione totale di Kim ($USD 2.61M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.17M ).
Compensazione vs guadagni: La retribuzione di Kim è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Kim Kelderman (57 yo)
less than a year
Mandato
US$6,852,495
Compensazione
Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$6.85m | 0.025% $ 3.1m | |
| Executive VP of Finance & CFO | 10.4yrs | US$5.20m | 0.063% $ 7.9m | |
| Senior VP | 1.5yrs | US$1.46m | 0.0011% $ 132.4k | |
| President of Protein Sciences Segment | 2.7yrs | US$3.65m | 0.0028% $ 349.7k | |
| President of Diagnostics & Genomics | less than a year | US$2.27m | Nessun dato | |
| VP & CTO | less than a year | Nessun dato | Nessun dato | |
| Senior Director of Investor Relations & Corporate Development | no data | Nessun dato | Nessun dato | |
| Vice President of Sales and Marketing | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Strategy & Corporate Development | less than a year | Nessun dato | Nessun dato | |
| Senior VP & Chief Human Resources Officer | no data | Nessun dato | Nessun dato | |
| Managing Director | 8.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Analytical Solutions Division | 1.7yrs | Nessun dato | Nessun dato |
1.1yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di TECH non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 1.7yrs | US$6.85m | 0.025% $ 3.1m | |
| Independent Chairman of the Board | 21.7yrs | US$410.46k | 0.027% $ 3.4m | |
| Independent Director | 15.3yrs | US$300.46k | 0.029% $ 3.7m | |
| Independent Director | 7.7yrs | US$275.46k | 0.0078% $ 969.2k | |
| Independent Director | 34.7yrs | US$276.92k | 0.015% $ 1.9m | |
| Independent Director | 14.3yrs | US$290.46k | 0.027% $ 3.4m | |
| Independent Director | 4.2yrs | US$291.50k | 0.0036% $ 447.1k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.3yrs | US$275.46k | 0.0050% $ 620.8k | |
| Independent Director | 7.7yrs | US$275.46k | 0.0078% $ 969.2k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato |
7.7yrs
Durata media
63yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TECH sono considerati esperti (durata media dell'incarico 7.6 anni).